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Summary: BMPRIA and its high-affinity ligand BMP4
have recently been shown to be expressed in the b-cells
of the pancreas. Here, we report the abnormalities of het-
erozygous mice for Bmpr1a in glucose metabolism dur-
ing the course of intraperitoneal glucose tolerance test.
The heterozygous mice had increased blood glucose lev-
els throughout the first 2.5 h after the administration of
glucose. Analysis of glucose-stimulated insulin secretion
(GSIS) indicates that insulin secretion in the heterozy-
gous mice is compromised, and induction of secreted in-
sulin by stimulation is substantially lower compared with
the wild-type controls. No apparent abnormalities in pan-
creas, thyroid, and liver were seen upon histological ex-
amination. Real-time PCR results of selected genes
showed an increase in the mRNA level of Ins1 and Ins2 in
the heterozygous group. These results indicate that the
glucose-sensing pathway in these heterozygous mice is
altered because of the heterozygosity in Bmpr1a. To-
gether, our data suggest that BMP signaling through
BMPRIA plays an important role in glucose metabolism
and possibly working through the GSIS pathway. genesis
47:385–391, 2009. VC 2009 Wiley-Liss, Inc.
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INTRODUCTION
Diabetes is a chronic, debilitating, and costly disease that
affects 20.8 million children and adults or 7% of the pop-
ulation in the United States. In type 2 diabetes, which
accounts for most of the cases, either the pancreas does
not produce enough insulin or the insulin is not prop-
erly utilized in maintaining the blood glucose level. Insu-
lin is produced by the b-cells in the pancreas, allowing
other cells in the body to utilize sugar molecules in the
blood stream. The cause of diabetes is largely unknown,
but genetic and environmental factors such as obesity
and lack of exercise seem to play a major role in the de-
velopment of this chronic disease. Many factors are
involved in regulating the blood glucose levels through
modulation of insulin secretion and/or its proper utiliza-
tion in glucose metabolism. In addition to glucose-stimu-
lated insulin secretion (GSIS) from pancreatic b-cells,
specific amino acids may acutely and chronically regu-
late insulin secretion from the b-cell (Newsholme et al.,
2007). Factors like free fatty acid and inflammatory adi-
pocytokines play a critical role in the development and
progression of diabetes (Pfeiffer, 2007). Decreased glu-
cose tolerance in diabetes may lead to impaired renal
function (Pessina, 2007). Increased blood glucose levels
from elevated hepatic glucose production may happen
because of diminished secretion of insulin, impaired
hepatic sensitivity to insulin action, or a combination of
both (Halter et al., 1985). Chronic inflammation and
developing insulin resistance are the two hallmarks of
type 2 diabetes. It has been reported that cytokines play
important roles in glucose metabolism besides their
immunoregulatory roles, and infusion of interleukin-6 in
healthy humans is shown to increase glucose disposal by
working like a hormone and to help increase fatty acid
oxidation (Pedersen, 2007).
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Other cytokines of interest include the TGF-b super-
family, and there is accumulating evidence that they play
an important role in the development of endocrine pan-
creas as well as in insulin secretion (Gannon, 2007).
TGF-b superfamily members, including TGF-b, activin,
and bone morphogenetic proteins (BMPs), have been
shown to be involved in islet morphogenesis and the
establishment of b-cell mass in several gene ablation or
overexpression studies in mice. Inhibition of TGF-b sig-
naling resulted in reduced beta cell mass and poorly
organized islets, which can be restored in overexpres-
sion studies using transgenic mice (Kim et al., 2000;
Sanvito et al., 1994; Smart et al., 2006; Yamaoka et al.,
1998). TGF-b signaling is involved in insulin production
and secretion in adult mice, whereas inhibition of activin
signaling resulted in significant decreases in insulin and
glucagon expression. There is also a substantial decrease
in the number and size of the islets in these mice
(Gannon, 2007).
BMPs were originally identified by their ability to
induce ectopic bone formation (Urist, 1965). These
secreted signaling molecules are involved in various cel-
lular processes including proliferation, differentiation,
and the determination of cell fate (Kishigami et al.,
2004). BMP4 has been reported to promote the expan-
sion of endocrine progenitor cells in the pancreas by
blocking their differentiation, and hence, balancing
between differentiation and expansion of pancreatic
duct epithelial progenitors (Hua et al., 2006). The role
of BMP2 in converting the acinar-like AR42J cells into in-
sulin-secreting b-cells in the presence of exendin-4 (glu-
cagons-like peptide 1) through the Smad pathway has
been reported recently, suggesting a role of BMP signal-
ing in b-cell formation (Yew et al., 2005).
BMPRIA (ALK3) is one of three type I receptors for
BMPs and is expressed in many tissues during develop-
ment as well as after birth (Kishigami and Mishina,
2005). The most studied ligands, BMP2 and BMP4, bind
to BMPRIA with high affinity, whereas BMP7 binds only
weakly to BMPRIA (Aoki et al., 2001) (Miyazono et al.,
2005). Mice homozygous for Bmpr1a null allele fail to
produce mesoderm and die at embryonic day 8.0 (E8.0)
(Mishina et al., 1995). Recently, it has been shown that
BMPRIA and its high-affinity ligand BMP4 are expressed
in differentiating and adult b-cells in the pancreas. Atte-
nuated BMPRIA signaling in the b-cells reduces the
expression of key genes that are involved in glucose
metabolism leading to the eventual onset of diabetes
(Goulley et al., 2007). Here, we studied heterozygous
knock out Bmpr1a to examine glucose metabolism. We
found that the 6-month-old heterozygous mice showed
increased blood glucose levels after intraperitoneal injec-
tion of glucose, despite their elevated levels of fasting
plasma insulin. Glucose stimulation to these mice indi-
cated that in fact, the mutant mice had impaired GSIS as
observed during intraperitoneal glucose tolerance test
(IPGTT). These results show that the heterozygous
Bmpr1a mice are morphologically indistinguishable
from their wild-type littermates, but manifested abnor-
malities in the glucose signaling pathway resulting in
impaired insulin secretion upon glucose stimulation.
RESULTS
Abnormal Glucose Metabolism During IPGTT
In multiple independent experiments, using different
groups of 6-month-old heterozygous mutant male mice
and their wild-type littermates, blood glucose values
rose substantially higher in the heterozygous Bmpr1a
mice (Fig. 1a). The increased blood glucose levels in the
heterozygous mice were maintained for the first 2.5 h
postglucose injection and gradually became insignificant
at 4 h postinjection. Beyond the increase in initial glu-
cose readings, 13 of the 33 heterozygous mutant mice
(39%) showed some form of glucose rebounding and
ineffective glucose control over a period of up to 2.5 h.
This abnormality presented in different manners, some-
times as oscillations, other times it might increase gradu-
ally over the 2.5 h period. Only one control mouse in 22
(4.5%) showed even a mild form of abnormal glucose
control. The same experiment performed on 3-month-
old mice did not show any overt changes between heter-
ozygous mice and control mice (data not shown). These
results suggest that the loss of one copy of the gene
causes the delay or reduction in the initial event
involved in the metabolism of sugar molecules including
the release of insulin in response to the demand.
Statistical Analysis of the IPGTT Data
For further comparison of glucose response over time
relative to the baseline values, we divided the observed
response at each time point by the response at the initial
time point. Because we expected an exponential decay in
response over time, we converted the data into log-scale.
In doing so, we generated a linear response over time,
and more importantly, the variability in response at each
time point was approximately constant and was normally
distributed (Fig. 1b). The two genotypes differed signifi-
cantly in their intercepts (P < 0.0001), confirming that
the heterozygous group had higher initial response to glu-
cose, relative to the baseline, than the control group of
animals. There was, however, no significant difference in
the slopes between the two genotypes (P 5 0.9337) (Ta-
ble 1). Thus, the rate of decay in glucose levels over time,
relative to the baseline values, did not differ significantly
between the heterozygous and control group. These anal-
yses highlight again that the heterozygous mice showed
insufficient response during the first phase.
Abnormalities in Insulin Secretion in the
Mutant Mice
There was a slightly elevated plasma insulin level in
the heterozygous mutant mice after an overnight fast
compared with the wild-type littermates (see Fig. 2).
This data indicate that the available insulin may not be
utilized properly in mutant mice, reflecting the scenario
of type 2 diabetes. Another likely possibility would be a
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defect in the GSIS pathway where the mutant mice do
not secrete enough insulin to handle the surge of glu-
cose in the plasma. To test this possibility, insulin levels
were measured after glucose stimulation. The mutant
mice had a much lower insulin release compared with
the control animals after glucose challenge (Fig. 2a). The
average percent change in insulin level between time 0
and 30-min postglucose injection was substantial. In
control animals, the average percent change was 74%,
whereas the mutant animals had only an 11% change
with a P-value of 0.03 (P 5 0.03) (Fig. 2b). These results
indicated that mutant mice not only had a poor response
to the glucose surge but also impaired GSIS.
FIG. 1. Analysis of IPGTT data using the glucose response and Scatter plot. (a) Graph of glucose response to IPGTT. The heterozygous
animals showed a larger response to the glucose challenge but tended to return back to resting levels at a normal rate. It is important to
note that the erratic nature of many of the heterozygous individuals is lost in the averaging. (b) Scatter plot of log ratios, relative to baseline,
of control (in blue) and heterozygous (in yellow), along with their respective linear regression lines. All the data points relative to the initial
fasting glucose level from the wild-type control mice (Wt) and heterozygous mice (Het) were averaged to determine the significance of the
values for intercept (a pink square and a cross on Y-axis) and the slope (a blue line and a yellow line) between the two genotypes.
Table 1
Statistical Analysis of the Intercept and the Slope
Intercept (SE) Slope (SE)
Wt 0.5512 (0.05978) 20.00359 (0.000236)
Het 0.7869 (0.05537) 20.00361 (0.000247)
Difference 0.2357 (0.08148) 20.00002 (0.000342)
P-value P < 0.0001 P5 0.9337
Values for intercepts and slopes were obtained from Figure 1b. As
shown in the table, there is no statistical significance between the
Wt and Het slopes but the difference in the intercept is highly
significant.
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Histological and Blood Chemistry Analysis of
Bmpr1a Heterozygous and Wild-Type Mice
Histological analysis was conducted on primary
organs involved in controlling blood glucose levels to
determine whether there was any gross structural or
organizational alteration. The pancreas showed islets
that were well formed, of normal size and general mor-
phology, and seemed to occur in a relatively normal
quantity (Fig. 3a,b). Besides pancreas, we also per-
formed the histological analyses on thyroid and liver.
The oscillations in blood glucose values after glucose ex-
posure prompted us to further analyze whether there is
any difference in thyroid hormones. There were no sig-
nificant differences in T3 (triiodothyronine) or T4 (thy-
roxine) values between the control and heterozygous
mutant mice (1.00 vs. 1.11 ng/ml for T3 and 4.00 vs.
4.35 mg/ml for T4). T3 and T4 values in mice can vary
substantially by strain and age, and many factors are
known to interfere including autoantibodies with thy-
roid hormone assays. Thyroid also appeared unremark-
able showing no overt phenotype (Fig. 3c,d). Liver was
selected for its role in overall glucose homeostasis and
glucose metabolism. Histological examination of the
liver revealed no gross abnormalities in the mutant heter-
ozygous mice (data not shown). It has been reported
that abnormally high fructosamine concentration in se-
rum correlates with suboptimal glycemic control in
humans (Yahaya et al., 2006). The mice, we examined,
however, showed no difference in fructosamine levels
between the two genotypes (data not shown). Overall,
no obvious differences between the heterozygous ani-
mals and the wild type littermates were observed in his-
tological analysis of the major three organs involved in
maintaining blood glucose levels or serum chemistry.
Gene Expression Analysis
Several genes involved in glucose regulation and me-
tabolism on both the liver and pancreas were selected
and tested whether their expression levels were altered
in the heterozygous mice. In the liver, Irs2 (insulin re-
ceptor substrate-2), Srebf1 (Sterol regulatory element
binding transcription factor 1), Srebp-1a, Srebp-1c), Gck
(glucokinase), and Gcg (glucagon) were all tested and
showed no significant changes in the heterozygous ani-
mals (data not shown). In the pancreas, we tested Pdx1
(pancreatic and duodenal homeobox 1, Ipf1), Ins1 (insu-
lin 1), Ins2 (insulin 2), Slc2a2 [solute carrier family 2
(facilitated glucose transporter), member 2, Glut2], and
Gck (Fig. 4a); although most showed an insignificant dif-
ference, the average Ins1 was increased over 50-fold in
the heterozygous mice, and Ins2 increased over 100-
fold. (Fig. 4b).
DISCUSSION
We report here an observed abnormality in glucose me-
tabolism in Bmpr1a heterozygous mice. The elevated
glucose response observed in 6-month-old heterozygous
male mice was consistent among different independent
experiments, which were performed using heterozygous
and wild-type mice. The higher glucose response in the
heterozygous mice was maintained for the first 2.5 h af-
ter glucose injection, and it became statistically insignifi-
cant thereafter in a 4-h experimental period. This indi-
cates that the initial signaling mechanism required to ini-
tiate the glucose metabolism pathway may have been
impaired in the heterozygous mice. If insulin resistance
in these mice is a possibility, that would make it a mouse
model similar to type 2 diabetes in humans.
Another possible explanation for this abnormality may
lie in GSIS where there may not be enough insulin avail-
able in the plasma for glucose disposal. Subsequent anal-
ysis of GSIS in these mice determined that the insulin
secretion pathway is impaired in the heterozygous ani-
mals. The initial insulin level in the heterozygous animals
was elevated after an overnight fast. The increase in insu-
lin after the glucose challenge, however, was much
lower in the heterozygous mice. Also of importance was
the notable inability of some mice to control their glu-
cose level after the initial response. Analysis of the indi-
FIG. 2. The average percent change in insulin level after glucose
stimulation. (a) The average change of insulin level between the het-
erozygous (Het) and the control (Wt) mice between 0- and 30-min
time period after glucose stimulation. (b) Percent change in serum
insulin levels. The percent change in control mice (Wt) is fivefold
higher than the heterozygous mice (Het) in that time period.
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vidual results showed that 39% of the heterozygous
group had some form of glucose rebounding or instabil-
ity, this would seem a considerable and significant por-
tion. This could possibly relate back to disrupted timing
in the secretions of the b-cells. Islets do secrete insulin
in bursts, and can vary, and even be modified in their fre-
quency (Ritzel et al., 2003). It is therefore possible that
the frequency of insulin secretion in heterozygous mice
is altered and perhaps inconsistent. Much of the differ-
ence in the two groups of mice came from this pheno-
typic 39%. In the only significant gene expression
results, Ins1 and Ins2 were increased over 50- and 100-
fold, respectively, in the heterozygous mice. Closer ex-
amination of the data showed that of the 10 heterozy-
gous mice tested for Ins1 and Ins2, none was in the nor-
mal range for both, and four (40%) showed an enormous
increase (>10-fold) of Ins1 and Ins2. However, the sim-
ple averages do not do justice to this data. The range of
results was remarkable in there own right, ranging from
0.40 to 324 fold induction in Ins1 and 0.34 to 958 fold
induction in Ins2. This would seem to point to another
compounding factor involved in this phenotype.
The consequence of increased Ins1 and Ins2 found
in insulinomas (Asfari et al., 1992) generally results in a
hypoglycemic state with increased insulin levels. In the
case of Bmpr1a heterozygous mice, despite higher Ins1
and Ins2 expression and elevated resting levels of
plasma insulin, they fail to respond to the increase in
blood glucose. These facts reinforce the idea that the
mutant mice cannot respond properly to a glucose chal-
lenge. There are significant examples linking the Tgf-b
family to INS, showing that Tgf-b1 increases insulin tran-
scription and release (Sayo et al., 2000). However, there
are examples that some human insulinomas show a
decrease of Tgf-b1 that results in a decrease of its target
genes including TGFBI and NMMT (Nabokikh et al.,
2007), suggesting relations between growth factor
signaling and insulin expression would be context
dependent. Despite accumulating reports describing
that BMPs stimulate differentiation of pancreatic cells
(Jiang and Harrison, 2005; Jiang et al., 2002), the only
study directly assessing Bmpr1a signaling on INS is
found in the pancreas-specific knockout study of
Bmpr1a (Goulley et al., 2007), which shows a reduction
in resting insulin secretion. The increase in Ins1 and
Ins2 and resting insulin after a reduction of Bmpr1a in
heterozygous mutant mice seems counter to these previ-
ous reports. This would suggest that either the cause of
the abnormal blood glucose response in the Bmpr1a
heterozygous mutant mice is located away from the pan-
creas, or, more likely, we have a situation where the phe-
notype is not simply dose dependent, and in fact it is the
reduced Bmpr1a expression in the pancreas that is re-
sponsible. It would seem very possible that an increase
of such magnitude in Ins-1 and Ins-2 could cause a sub-
sequent reduction of a similar magnitude in the insulin
receptor substrates, or their downstream targets, result-
ing in the inability to respond to the increase in glucose.
Further in vitro and in vivo work will elucidate the exact
cause of this inconsistency in insulin secretion.
To determine whether the heterozygous mice suffer
any form of hypothyroidism, we tested T3 and T4 levels
FIG. 3. Histological analysis of
pancreas and thyroid using H&E
staining. Histology of thyroid (a, b)
and pancreas (c, d), where panels
a, c and b, d correspond to the
wild type and heterozygous mice,
respectively. Paraffin sections
were stained with hematoxylin
and eosin. No gross abnormalities
were observed in either tissue. F,
denotes the follicle and the bar
represents 200 lm (340 original
magnification).
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in these animals. T3 and T4 values in the heterozygous
animals were not different from those of the control ani-
mals and fell in the normal range. The heterozygous
mice showed no difference in fructosamine level from
that of the controls as well.
Overall, these heterozygous mice could well be used
for further study to reveal the molecular mechanisms
involved in this glucose intolerance, and would be inter-
esting to explore how BMPRIA signaling is linked to nor-
mal glucose metabolism. Although the broad ranging
and sometimes inconsistent phenotypes of heterozygous
mice make them difficult to study, their potential appli-
cation to human conditions seems to demand that we
look further in this area.
METHODS
Generation of Mutant Bmpr1a Mutant Mice
Generation of the mutant Bmpr1a mouse line was
described previously (Mishina et al., 1995). Heterozy-
gous mice were maintained in mixed 129SvEv and
C57BL/6 background. Animal protocols were approved
by the Institutional Animal Care and Use Committee at
the National Institute of Environmental Health Sciences,
NIH.
Intraperitoneal Glucose Tolerance Test
Mice were subjected to an overnight fast (greater than
6 h) with access to drinking water. Mice were weighed
the next morning and a fasting glucose level was
obtained. Blood was collected from the lateral marginal
vein in the hind leg, and glucose levels were measured
using a Glucometer (Accu-Chek, Roche, NJ). Glucose
(2,000 mg/kg) was injected intraperitoneally according
to the weight of the individual mouse, and blood glucose
levels were measured at either 20, 40, 60, 90, 120, 150,
and 240 min or 30, 60, 90, 120, 150, and 240 min
postinjection.
Enzyme-Linked Immunosorbent Assay
Serum insulin levels were measured by ELISA (Linco
Research, Charles, MO) following the protocol supplied
by the manufacturer. Three wild type and five heterozy-
gous mice each had 20 ll of blood drawn by subman-
dibular puncture at time 0- and 30-min postglucose injec-
tion. Blood was allowed to clot and spun at 2,500g for
15 min at 48C in hemostat tubes to separate serum.
Histology
Tissue samples were collected from animals after
standard CO2 euthanasia. Liver, pancreas, and thyroid
glands were removed, fixed in 10% formalin, and embed-
ded in paraffin for sectioning. Tissue was sectioned at 8
lm and stained with standard H&E protocol.
Gene Expression
Three wild type and 3–10 heterozygous individuals
were selected for RNA extraction and real-time analysis.
RNA was collected from both the liver and pancreas
using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA
was then made using superscript II (Invitrogen, Carls-
bad, CA). Real-time PCR was done using Power SYBR
Green from Applied Biosystems (Foster City, CA). All
cycles were run with an annealing temperature of 588C,
and all samples were run in at least triplicate and com-
pared using the 2DDt method (Livak and Schmittgen,
2001).
Statistical Methods
Because repeated measurements are recorded on each
animal, we expect the responses within animals to be
correlated. To account for this correlation, we used
FIG. 4. Real-time RT PCR analysis. Real-time analysis of selected
genes revealed that most of the tested genes were not modified in a
substantial way (a). The only genes showing any significant changes
were Ins1 and Ins2, with average increases over 50- and 100-fold,
respectively (b). Relative expression of genes shown in fold increase
on a log10 scale. k5WT, h5 Hets.
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mixed effects models by treating animals as random
effects. Using PROC MIXED (statistical software package
SAS, version 9.1.3), we fitted a linear regression model
with an intercept and a slope for each genotype.
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